Basit öğe kaydını göster

dc.contributor.authorBasaranoglu, Sevgen Tanir
dc.contributor.authorOncel, Eda Karadag
dc.contributor.authorAykac, Kubra
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorCengiz, Ali Bulent
dc.contributor.authorKara, Ates
dc.contributor.authorCeyhan, Mehmet
dc.date.accessioned2019-12-10T10:39:15Z
dc.date.available2019-12-10T10:39:15Z
dc.date.issued2017
dc.identifier.issn2164-5515
dc.identifier.urihttps://doi.org/10.1080/21645515.2016.1256519
dc.identifier.urihttp://hdl.handle.net/11655/14107
dc.description.abstractA breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.isversionof10.1080/21645515.2016.1256519
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiotechnology & Applied Microbiology
dc.subjectImmunology
dc.titleInvasive Pneumococcal Disease: From a Tertiary Care Hospital in the Post-Vaccine Era
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalHuman Vaccines & Immunotherapeutics
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları
dc.identifier.volume13
dc.identifier.issue4
dc.identifier.startpage962
dc.identifier.endpage964
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster